References
- Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001; 121: 710–23
- Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liv Dis 2001; 21: 17–26
- Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113–121
- Ishii H. Common pathogenic mechanisms in ASH and NASH. Hepatol Res 2004; 28: 18–20
- McCuskey RS, Ito Y, Robertson GR, McCuskey MK, Perry M, Farrell GC. Hepatic microvascular dysfunction during evolution of dietary steatohepatitis in mice. Hepatology 2004; 40: 386–93
- Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor α signaling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 2006; 55: 415–24
- Shiomi S, Kuroki T, Ueda T, Takeda T, Nishiguchi S, Nakajima S, et al. Diagnosis by routine scintigraphy of hepatic reticuloendothelial failure before severe liver dysfunction. Am J Gastroenterol 1996; 91: 140–2
- Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313–21
- Youden WJ. An index for rating diagnostic tests. Cancer 1950; 3: 32–5
- Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006; 163: 670–5
- Tanaka S, Kumashiro R, Tanikawa K. Role of the spleen in endotoxin-induced hepatic injury in chronic alcohol-fed rats. Liver 1992; 12: 306–12
- Riordan SM, Duncombe VM, Thomas MC, Nagree A, Bolin TD, Mclver CJ, et al. Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. Gut 2002; 50: 136–8
- Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206–11
- Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343–50
- Groshar D, Slobodin G, Zuckerman E. Quantitation of liver and spleen uptake of 99mTc-phytate colloid using SPECT: detection of liver cirrhosis. J Nucl Med 2002; 43: 312–7
- Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003; 38: 32–8
- Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255–9
- Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745–50